Grit S Herter-Sprie
Overview
Explore the profile of Grit S Herter-Sprie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
2594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ibruli O, Rose F, Beleggia F, Schmitt A, Cartolano M, Fernandez L, et al.
J Cancer Res Clin Oncol
. 2024 Nov;
150(11):496.
PMID: 39542886
Purpose: Small cell lung cancer (SCLC) has an extremely poor prognosis. Despite high initial response rates to chemotherapy and modest survival improvements with the addition of immune checkpoint inhibitors (ICI),...
2.
Kiljan M, Weil S, Vasquez-Torres A, Hettich M, Mayer M, Ibruli O, et al.
Int J Radiat Biol
. 2021 May;
97(9):1261-1269.
PMID: 34043466
Purpose: Radiation therapy (RT) is a common nonsurgical treatment in the management of patients with cancer. While genetically engineered mouse models (GEMM) recapitulate human disease, conventional linear particle accelerator systems...
3.
Herter-Sprie G, Korideck H, Christensen C, Herter J, Rhee K, Berbeco R, et al.
Nat Commun
. 2020 Apr;
11(1):1835.
PMID: 32273495
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
4.
Haines E, Chen T, Kommajosyula N, Chen Z, Herter-Sprie G, Cornell L, et al.
Oncotarget
. 2018 Sep;
9(60):31572-31589.
PMID: 30167080
CDK4 is emerging as a target in -mutant non-small cell lung cancer (NSCLC). We demonstrate that -mutant NSCLC cell lines are initially sensitive to the CDK4/6 inhibitor palbociclib, but readily...
5.
Li S, Liu S, Deng J, Akbay E, Hai J, Ambrogio C, et al.
Clin Cancer Res
. 2018 Jun;
24(19):4854-4864.
PMID: 29945997
Despite the challenge to directly target mutant KRAS due to its high GTP affinity, some agents are under development against downstream signaling pathways, such as MEK inhibitors. However, it remains...
6.
Deng J, Wang E, Jenkins R, Li S, Dries R, Yates K, et al.
Cancer Discov
. 2017 Nov;
8(2):216-233.
PMID: 29101163
Immune checkpoint blockade, exemplified by antibodies targeting the PD-1 receptor, can induce durable tumor regressions in some patients. To enhance the efficacy of existing immunotherapies, we screened for small molecules...
7.
Zhang H, Brainson C, Koyama S, Redig A, Chen T, Li S, et al.
Nat Commun
. 2017 Jun;
8:15901.
PMID: 28598439
This corrects the article DOI: 10.1038/ncomms14922.
8.
Zhang H, Brainson C, Koyama S, Redig A, Chen T, Li S, et al.
Nat Commun
. 2017 Apr;
8:14922.
PMID: 28387316
Adenosquamous lung tumours, which are extremely poor prognosis, may result from cellular plasticity. Here, we demonstrate lineage switching of KRAS+ lung adenocarcinomas (ADC) to squamous cell carcinoma (SCC) through deletion...
9.
Awad M, Jones R, Liu H, Lizotte P, Ivanova E, Kulkarni M, et al.
Cancer Immunol Res
. 2016 Nov;
4(12):1038-1048.
PMID: 27856426
PD-L1 immunohistochemical staining does not always predict whether a cancer will respond to treatment with PD-1 inhibitors. We sought to characterize immune cell infiltrates and the expression of T-cell inhibitor...
10.
Herter-Sprie G, Koyama S, Korideck H, Hai J, Deng J, Li Y, et al.
JCI Insight
. 2016 Oct;
1(9):e87415.
PMID: 27699275
Radiation therapy (RT), a critical modality in the treatment of lung cancer, induces direct tumor cell death and augments tumor-specific immunity. However, despite initial tumor control, most patients suffer from...